Phreesia, Inc. (NYSE:PHR - Get Free Report) insider Yvonne Hui sold 571 shares of the firm's stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $28.85, for a total transaction of $16,473.35. Following the completion of the transaction, the insider directly owned 31,010 shares in the company, valued at $894,638.50. This represents a 1.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Yvonne Hui also recently made the following trade(s):
- On Tuesday, June 10th, Yvonne Hui sold 582 shares of Phreesia stock. The stock was sold at an average price of $28.00, for a total transaction of $16,296.00.
- On Monday, April 21st, Yvonne Hui sold 993 shares of Phreesia stock. The stock was sold at an average price of $23.04, for a total transaction of $22,878.72.
- On Tuesday, April 15th, Yvonne Hui sold 314 shares of Phreesia stock. The stock was sold at an average price of $24.04, for a total transaction of $7,548.56.
Phreesia Price Performance
NYSE:PHR traded up $0.52 during trading hours on Wednesday, reaching $28.93. 381,937 shares of the company's stock were exchanged, compared to its average volume of 458,425. The company has a market capitalization of $1.72 billion, a P/E ratio of -39.09 and a beta of 0.72. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $30.53. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.02. The business's 50-day simple moving average is $26.17 and its two-hundred day simple moving average is $26.31.
Phreesia (NYSE:PHR - Get Free Report) last issued its earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.06. The firm had revenue of $115.94 million during the quarter, compared to analysts' expectations of $115.00 million. Phreesia had a negative net margin of 9.83% and a negative return on equity of 16.23%. The firm's revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.05) earnings per share. Sell-side analysts expect that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.
Analyst Ratings Changes
A number of brokerages recently issued reports on PHR. Wall Street Zen raised Phreesia from a "hold" rating to a "buy" rating in a report on Sunday, June 1st. Citigroup reissued a "buy" rating on shares of Phreesia in a research note on Wednesday, May 28th. Truist Financial raised their price target on Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, May 29th. Needham & Company LLC reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Phreesia in a report on Thursday, March 13th. Finally, DA Davidson lowered their target price on shares of Phreesia from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $31.64.
Read Our Latest Analysis on Phreesia
Hedge Funds Weigh In On Phreesia
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Phreesia by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 4,936,515 shares of the company's stock valued at $126,177,000 after buying an additional 113,405 shares during the period. Greenhouse Funds LLLP boosted its stake in shares of Phreesia by 2.9% during the 1st quarter. Greenhouse Funds LLLP now owns 2,956,910 shares of the company's stock valued at $75,579,000 after buying an additional 83,018 shares during the period. Champlain Investment Partners LLC boosted its stake in shares of Phreesia by 20.0% during the 1st quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company's stock valued at $75,312,000 after buying an additional 490,340 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Phreesia by 108.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company's stock valued at $67,606,000 after buying an additional 1,377,904 shares during the period. Finally, Franklin Resources Inc. boosted its stake in shares of Phreesia by 0.8% during the 4th quarter. Franklin Resources Inc. now owns 1,509,617 shares of the company's stock valued at $37,982,000 after buying an additional 11,986 shares during the period. Institutional investors and hedge funds own 92.10% of the company's stock.
About Phreesia
(
Get Free Report)
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Featured Articles

Before you consider Phreesia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list.
While Phreesia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.